Background: Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis. Both cetuximab and endostatin have been found to reduce the expression of endothelial-stimulating growth factors such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8. However, the effects of cetuximab alone or in combination with endostatin on human lung adenocarcinoma cell growth remain unclear.
Methods:
The epidermal growth factor receptor (EGFR) status of a panel of human lung adenocarcinoma cell lines was characterized using Western blot analysis. We used a modified tetrazolium salt assay to evaluate the growth-inhibitory effects of cetuximab and endostatin alone and in combination on the cell lines. We also determined the effects of these 2 drugs on VEGF and IL-8 expression using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Cells were treated for 4 days with cetuximab 12.5 μg/mL, endostatin 25 μg/mL, or cetuximab 12.5 μg/mL + endostatin 25 μg/mL. Untreated cells cultured for 4 days served as controls.
Results: EGFR expression in the H1299 cells was higher than in the SPC-A1 and H460 cells. Varying concentrations of cetuximab alone were associated with a significant growth-inhibitory effect on all 3 cell lines in a dose-dependent manner after 4 days of exposure compared with controls (all, P < 0.05). Compared with controls, varying concentrations of endostatin alone were not associated with significant inhibition of cell growth in any of the 3 cell lines. The inhibitory ratio of cetuximab + endostatin at varying concentrations was significantly greater than that of cetuximab alone (all, P < 0.05). On ELISA, either drug alone was associated with significant reductions in secreted VEGF and IL-8 in the H1299, SPC-A1, and H460 cell lines (all, P < 0.05), with the exception of IL-8 concentration in the H460 cells. Mean (SD) VEGF expression with combination treatment in the H1299 and SPC-A1 cell lines (687 [21] and 629 [23] pg/mL, respectively) was significantly lower than with cetuximab alone (878 [31] and 708 [20] pg/mL; both, P < 0.001); in the H460 cell line, combination treatment was not associated with a significant further reduction in VEGF expression. IL-8 concentrations with cetuximab in the H1299, SPC-A1, and H460 cell lines were 628 (20) , 484 (29) , and 532 (28) pg/mL, respectively, while the IL-8 concentrations with the combination treatment were 516 (20) , 480 (18) , and 467 (30) pg/mL. An enhanced effect of endostatin on IL-8 was observed in the H1299 and H460 cell lines (P < 0.001 and P = 0.018, respectively); however, no enhanced effect in the SPC-A1 line was observed. Similar results for VEGF and IL-8 expression were found using Western blot analysis.
Conclusions:
The results from this in vitro study suggest that cetuximab treatment might both inhibit human lung adenocarcinoma cell line growth and reduce the expression of VEGF and IL-8, which are the biomarkers of angiogenesis. Endostatin was not associated with inhibition of human lung adenocarcinoma cell line growth directly. Findings with the combination of cetuximab + endostatin suggest that endostatin might enhance the antiangiogenic and antitumor activity of cetuximab through an apparent effect on VEGF expression and, to a lesser degree, on IL-8 expression. 
INTRODUCTION
Angiogenesis is a crucial factor in increased invasiveness and widespread metastases in a variety of human neoplasms. 1 Such tumors overexpress the angiogenic factors, including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), interleukin (IL)-8, and platelet-derived growth factor (PDGF), which are important in regulating tumor-host interactions that result in tumor neovascularization.
The transforming growth factor-α (TGF-α)-epidermal growth factor receptor (EGFR) signaling pathway plays an important role in the development and progression of human epithelial cancers. 2 Overexpression of EGFR has been detected in many human carcinomas, including non-small cell lung cancer (NSCLC), [2] [3] [4] and is generally an indicator of poor prognosis. 5 Recently, the link between the EGFR signaling pathway and angiogenesis was identified. Both EGF and TGF-α, ligands for EGFR, have been reported to induce angiogenesis. [6] [7] [8] Targeted biologic therapies that selectively interfere with tumor angiogenesis could improve survival among patients with lung cancer. The interest in EGFR-targeting drugs resulted in the development of cetuximab (also known as C225) in the past 5 years. Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that binds to EGFR with high specificity and with a higher affinity than EGFs, thereby blocking ligand-induced phosphorylation of EGFR and strongly inhibiting EGFR-dependent tumor angiogenesis. 9 Endostatin is another tumor-derived angiogenesis inhibitor and is the first endogenous inhibitor of angiogenesis to be identified in a matrix protein.
It is a 20-kDa internal fragment of the carboxyterminus of collagen XVIII, [10] [11] [12] specifically inhibiting the proliferation and migration of endothelial cells and inducing their apoptosis with no direct cytotoxic effect on tumor cells. 10, [13] [14] [15] Based on a PubMed search (key terms: endostatin, lung neoplasms, and cetuximab; years: 1974-2008), little information is available about the effects of cetuximab in combination with endostatin on human lung adenocarcinoma cells. The aim of this study was to investigate the growth-inhibitory effects of cetuximab alone and in combination with endostatin in the human lung adenocarcinoma cell lines H1299, SPC-A1, and H460 in vitro. VEGF and IL-8 expression in these cell lines when treated with the blocking anti-EGFR cetuximab and angiogenesis inhibitor endostatin were also investigated.
MATERIALS AND METHODS

Cell Cultures
Human lung adenocarcinoma cell lines H1299, SPC-A1, and H460 were obtained from the Shanghai Institute of Thoracic Oncology (Shanghai, People's Republic of China). All cell lines were cultured and maintained in Dulbecco's modified Eagle's medium (Grand Island Biological Company, Grand Island, New York) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Shanghai ChangDao, Bio-TECH, Shanghai, People's Republic of China), 100 U/mL of penicillin, and 100 μg/mL of streptomycin in a humidified incubator with 5% carbon dioxide.
Growth Inhibition of Human Lung Adenocarcinoma Cells
The growth-inhibitory effects of cetuximab and endostatin alone and in combination were evaluated using a modified tetrazolium salt (MTT) assay. 16 In the MTT assay, ~2000 viable cells were plated in 100 μL of growth medium in 96-well plates. After overnight incubation, varying concentrations of cetuximab (12.5, 25 , and 50 μg/mL), endostatin, and the combination of cetuximab + endostatin were added to the plates, and the cells were incubated with MTT for 4 days. Tetrazolium salt 0.5 mg/mL was added to each well. The plates were incubated with the salt for 4 hours at 37°C and the medium was removed using aspiration, leaving the dark-blue formazan product at the bottom of the wells. The reduced MTT product was solubilized by adding 150 μL of dimethyl sulfoxide and was vortexed for 10 minutes. The absorbancy of each well was measured using an automated plate reader (Bio-RAD Laboratories, Hercules, California). All experiments were done in triplicate.
Enzyme-Linked Immunosorbent Assay
Enhanced expression of angiogenic factors VEGF 17 and IL-8 [18] [19] [20] has been detected in the majority of human carcinomas. We therefore used enzyme-linked immunosorbent assay (ELISA) to observe whether the secreted protein production of VEGF and IL-8 was downregulated when the cell lines were treated with cetuximab, endostatin, or cetuximab + endostatin.
The effects of combination treatment were examined using an MTT assay. The combination cetuximab 12.5 μg/mL + endostatin 25 μg/mL was found to produce an inhibitory ratio of ~50% in H1299, SPC-A1, and H460 cells. We treated tumor cell lines with cetuximab 12.5 μg/mL, endostatin 25 μg/mL, and cetuximab 12.5 μg/mL + endostatin 25 μg/mL in 96-well plates. After 4 days of incubation, supernatant from varying doses of the drugs was collected for ELISA. The concentrations of VEGF and IL-8 were measured using a commercially available ELISA kit according to the manufacturer's instructions (Shanghai Westtang BIO-TECH, Shanghai, People's Republic of China).
Western Blot Analysis
In the Western blot analysis, ~50,000 viable cells were plated in 100-mm-diameter dishes. For the detection of EGFR expression, the cells were collected after 4 days of incubation without any drugs. For the detection of expression of VEGF and IL-8, cetuximab 12.5 μg/mL, endostatin 25 μg/mL, and cetuximab 12.5 μg/mL + endostatin 25 μg/mL were added to the dishes, and the cells were incubated with varying doses of the drugs for 4 days. The cells were rinsed once with ice-cold phosphatebuffered saline and the radio-immunoprecipitation assay lysis buffer 100 μL was added. The cells were scraped off the dishes and incubated on ice for 30 minutes. The mixture was centrifuged at 12,000 rpm for 10 minutes at 4°C in preparation for Western blot analysis. Approximately 30 μg of proteins extracted from the tumor cells was loaded on an SDS/8% (w/v) polyacrylamide gel. For VEGF and IL-8, SDS/15% (w/v) polyacrylamide gel was used. Following electrophoresis, the proteins were transferred to a polyvinylidene fluoride membrane. After the blocking mixture was added, the membranes were hybridized with antibodies against VEGF (1:200 dilution; Abcam Ltd., Cambridge, United Kingdom), IL-8 (1:300 dilution; Abcam Ltd.), and EGFR (1:250 dilution; Abcam Ltd.) in tris-buffered saline-T buffer with 5% nonfat dry milk overnight at 4°C. Bound antibodies were detected using antirabbit horseradish peroxidase conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, California) with 1:2500 dilution and using an enhanced chemiluminescence system (Amersham Biosciences, Piscataway, New Jersey). Normalization of total loaded proteins was obtained by immunodetection of glyceraldehyde 3-phosphate dehydrogenase on the same blotted membrane with specific antibodies (Santa Cruz Biotechnology, Inc.).
Statistical Analysis
In the MTT assay, the mean difference in absorbance was compared between treatments and controls using the Dunnett t test. An independent-samples t test was done to compare the inhibitory ratios of cetuximab + endostatin to those of cetuximab alone. In ELISA, the least significant differences test was used to compare the difference between cetuximab alone or endostatin alone and controls and the difference between cetuximab + endostatin and cetuximab alone. A difference of P < 0.05 was considered significant. Statistical analysis was performed using SPSS version 11.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Epidermal Growth Factor Receptor Expression in Human Lung Adenocarcinoma Cells
The intensity of EGFR staining was greater in the H1299 cells than in the SPC-A1 cells, while the expression of EGFR was lowest in the H460 cells. The intensity of EGFR staining was greater in the H1299 cells than in the SPC-A1 cells, while the expression of EGFR was lowest in the H460 cells (Figure 1) .
In Vitro Cell Growth Inhibition
In vitro treatment of cell lines with cetuximab was associated with dose-dependent cytostasis ( Table I) . Compared with controls, cetuximab treatment was associated with significantly inhibited growth of the H1299 cell line, which had the greatest EGFR expression; the inhibitory ratios of cetuximab 12.5, 25, and 50 μg/mL were 0.27, 0.35, and 0.47, respectively (all, P < 0.05). Compared with controls, cetuximab was associated with moderate inhibition of the growth of SPC-A1 cells (0.18, 0.26, and 0.40; all, P < 0.05), which had intermediate EGFR expression. The growth of the H460 cell line was found to be significantly less inhibited with cetuximab compared with that of the H1299 and H460 cell lines (inhibitory ratios, 0.17, 0.20, and 0.34; all, P < 0.05). The maximum inhibition observed with cetuximab was 47% after 4 days of continuous exposure at the highest dose (50 μg/mL). Endostatin was not associated with significant growth inhibition of any of the cell lines.
The inhibitory ratios with cetuximab 12.5 to 50 μg/mL + endostatin 12.5 to 50 μg/mL are summarized in Table II . The inhibitory ratios with cetuximab + endostatin at varying concentrations were found to be significantly greater than those with cetuximab alone (all, P < 0.05). The 50% inhibitory concentrations ob- served in the H1299, SPC-A1, and H460 cell lines all occurred with cetuximab 12.5 μg/mL + endostatin 25 μg/mL.
Downregulation of Vascular Endothelial Growth Factor and Interleukin-8 in Human Lung Adenocarcinoma Cells
Secreted VEGF and IL-8 protein in the H1299 and SPC-A1 cell lines were significantly inhibited by either cetuximab or endostatin alone (all, P < 0.05) ( Table III) . With combination treatment in the H1299 cell line, endostatin seemed to enhance the inhibitory effect of cetuximab on VEGF and IL-8 (687 [21] and 516 [20] pg/mL, respectively) compared with cetuximab alone (878 [31] and 628 [20] pg/mL; both, P < 0.001). In the SPC-A1 cell line, the addition of endostatin to cetuximab was associated with a significantly lower VEGF expression beyond the reduction found with cetuximab alone (629 [23] vs 708 [20] pg/mL; P = 0.014). The addition of endostatin to cetuximab, however, was not associated with significantly lower IL-8 expression beyond the reduction found with cetuximab alone in the SPC-A1 cell line (480 [18] vs 484 [29] pg/mL). In the H460 cell line, the VEGF concentrations were significantly inhibited with either drug alone (both, P < 0.001), but the addition of endostatin was not associated with enhancement of the inhibitory effect of cetuximab. In the H460 cell line, neither cetuximab nor endostatin alone was associated with signifi- cantly lower IL-8 concentrations (532 [28] and 523 [17] pg/mL), but combination treatment was associated with significantly greater inhibition of IL-8 expression (467 [30] pg/mL) compared with cetuximab (P = 0.018). Similar results were obtained on Western blot analysis. Reductions in VEGF and IL-8 expression were found with drug treatment in the H1299 and SPC-A1 cell lines compared with controls. In the H460 cell line, reductions in VEGF with either drug alone or combination treatment were not significantly different compared with controls. IL-8 concentrations were not reduced significantly with either drug alone compared with controls; however, combination treatment was associated with significant inhibition of IL-8 expression compared with controls (Figure 2) .
DISCUSSION
Angiogenesis plays a crucial role in increasing the invasiveness of, and the metastases in, various human carcinomas. Previous studies have found that neoplasms frequently have high expression of the angiogenic factors, including bFGF, VEGF, IL-8, and PDGF. 19, [21] [22] [23] The link between EGFR signaling and angiogenesis has been clearly identified. [6] [7] [8] The monoclonal antibody cetuximab (C225), an inhibitor of EGFR, has been found to have downregulated angiogenic factors by blocking the EGFR signal pathway and to have inhibited the growth of some EGFR-overexpressing cell lines of various histologies, including NSCLC, both in vitro and in vivo. [24] [25] [26] [27] The present study characterized a panel of human lung adenocarcinoma cell lines of various EGFR expression using Western blot analysis. EGFR expression in the H1299 cell line was higher than in the SPC-A1 and H460 lines. All 3 cell lines expressed EGFR, which was potentially sensitive to cetuximab.
Endostatin, a 20-kDa C-terminal fragment of type XVIII collagen, was the first endogenous inhibitor of angiogenesis to be identified. Some experimental studies have found that recombinant endostatin reduced experimental tumors to a dormant state. 11, [28] [29] [30] This study found that cetuximab was associated with a significant inhibition of the growth of these 3 EGFR-expressing cell lines. It appeared that cells with higher levels of EGFR expression were more sensitive to cetuximab. Endostatin was not associated with inhibition of the growth of any of the cell lines, but it was associated with a significantly enhanced inhibitory effect of cetuximab. Combination treatment with these 2 drugs was associated with a greater inhibitory effect compared with treatment with either drug alone.
Endothelial-stimulating growth factors (eg, VEGF 31 , IL-8 [32] [33] [34] [35] ) provide survival signals to the activated endothelial cells during angiogenesis. Based on the results found with either drug alone compared with the combination treatment on these biomarkers of angiogenesis in the present study, the additive effects of endostatin could be attributed to its effect on VEGF expression and, to a lesser degree, on IL-8 expression. IL-8 expression apparently was not affected in the H460 cell line by these 2 drugs; this finding might correlate with EGFR expression, which was much lower in H460 than H1299 and SPC-A1. This finding might also mean that there exists some unclear mechanism leading to cetuximab and endostatin resistance. 
CONCLUSIONS
Data from this study suggest that cetuximab treatment had a growth-inhibitory effect in vitro that was attributable to direct blockade of the EGFR-dependent mitogenic pathway. The drug was associated with inhibited human lung adenocarcinoma cell line growth and with reduced expression of VEGF and IL-8, which are the biomarkers of angiogenesis. Endostatin was not associated with downregulated expression of VEGF and IL-8, although a direct inhibitory effect on growth of the H1299, SPC-A1, and H460 cell lines was apparent. Results with combination treatment suggested that endostatin might enhance the antiangiogenic and antitumor activity of cetuximab. Further studies are needed.
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